Platelet vesicular monoamine transporter 2 density in the disruptive behavior disorders

Gil Zalsman*, Dorit Aslanov-Farbstein, Moshe Rehavi, Netta Roz, Robert Vermeiren, Nathaniel Laor, Avraham Weizman, Paz Toren

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


In a former study, we reported decreased platelet vesicular monoamine transporter 2 (VMAT2) density (Bmax) in patients with ADHD. The current study aimed at measuring platelet VMAT2 in the disruptive behavior disorders (DBDs) to assess whether this finding is specific to ADHD or generalizable to the broader DBD concept. The study included 13 patients with DBDs aged 10-12 years and 16 healthy volunteers aged 8-17 years. All participants underwent a thorough clinical evaluation using Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version for diagnosis, the Nisonger Child Behavior Rating Form, the Clinical Global Impressions Scale-Severity version, and the DSM-IV ADHD Scale (DAS). The study group's DAS scores did not differ from those of the control group. There was no significant difference between the patients with DBDs and the control group either in VMAT2 density (Bmax) or affinity (Kd) as measured by high-affinity [ 3H]TBZOH binding. We conclude that the formerly reported decreased platelet VMAT2 Bmax in patients with ADHD may be specific to ADHD and not present in DBDs. Larger-scale replication is needed.

Original languageEnglish
Pages (from-to)341-344
Number of pages4
JournalJournal of Child and Adolescent Psychopharmacology
Issue number4
StatePublished - 1 Aug 2011


Dive into the research topics of 'Platelet vesicular monoamine transporter 2 density in the disruptive behavior disorders'. Together they form a unique fingerprint.

Cite this